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COVID-19-associated vasculitis and thrombotic
complications: from pathological findings to
multidisciplinary discussion
SIR, Thrombosis in patients with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection repre-
sents the most relevant extra-pulmonary manifestation
of COVID-19 and recognizes a multifactorial pathogen-
esis [1]. Cases of SARS-CoV-2 disease (COVID-19)-
related vasculitis are reported in the literature [2–9] and
this could represent a possible alternative mechanism of
arterial thrombosis secondary to inflammation in COVID-
19. Herein, we report the first case of neutrophilic arter-
ial vasculitis in COVID-19.
A 73-year–old man with a past history of type II dia-
betes, chronic kidney disease (CKD) and ischaemic cor-
onary disease was admitted to the University Hospital of
Modena for shortness of breath and dry cough. Oro-
rhino-pharyngeal swab was positive for SARS-CoV-2
and radiological findings showed interstitial pneumonia.
At admission, he had abdominal pain, decompensated
ketoacidosis, and acute on CKD (stage 3 b) although he
had no respiratory failure (PaO2/FiO2¼ 341 mmHg). He
received antithrombotic prophylaxis with low-molecular-
weight heparin (LMWH) (4000 U once a day) and contin-
ued previous therapy with acetylsalicylic acid (100 mg
once a day). Laboratory exams revealed elevated CRP
(48 mg/dl) and D-dimer (6910 ng/ml) with normal pro-
thrombin time and activated partial thromboplastin time.
The Sequential Organ Failure Assessment (SOFA) score
was 2. Antiphospholipid antibodies were not detected.
The following day he presented an acute abdomen.
Angio-CT showed arterial multifocal thrombosis with
total occlusion involving coeliac tripod and superior
mesenteric artery with splenic and distal ileum infarction
(Fig. 1A). He underwent splenectomy and resection of
the ischaemic bowel loop. Two days after surgery, he
was discharged from the Intensive Care Unit. He has
never been subjected to mechanical ventilation. His
post-surgery course was characterized by a second epi-
sode of diabetic decompensation, intra-abdominal infec-
tion and acute exacerbation of CKD requiring temporary
haemodialysis. Sixteen days after the first test, oro-
rhino-pharyngeal swab for SARS-CoV-2 turned negative.
Sixty days after admission, the patient is still
hospitalized. Surgical complications led to prolonged
hospitalization due to nosocomial infections that neces-
sitated specific treatment, such as central venous
catheter-related candidemia and infection of a sacral
decubitus plaque. Then, in consideration of the patient’s
frailty, he underwent a careful and prolonged rehabilita-
tion programme.
Histopathological findings confirmed mesenteric and
splenic thrombosis with a large splenic infarction. In the
splenic hilar area, thrombotic material was observed in
the lumen of venous (Fig. 1B) and arterial blood vessels
(Fig. 1C). The arterial wall showed transmural necrosis
with massive infiltration of neutrophils, mainly in the ad-
ventitia and media, the intima being less affected
(Fig. 1D and E), providing a histopathological diagnosis
of neutrophilic vasculitis. Veins were not involved in the
vasculitic process. SARS-CoV-2 was not detected by
PCR performed on a paraffinized splenic artery wall
specimen.
As the patient’s clinical condition significantly
improved after surgery, no immunosuppressive therapy
was initiated, despite the detection of arterial vasculitis.
This complex case scenario and the potential related
clinical implications required multidisciplinary discussion
among haematologist, rheumatologist, pneumologist
and nephrologist. Herein, we report the main issues
addressed by each specialist.
The haematologic perspective: thrombosis related
to inflammation is described both in systemic inflamma-
tory response syndrome and in decompensated
ketoacidosis [10]. Recent evidence suggests that
patients with severe COVID-19 often meet sepsis-
induced coagulopathy criteria and may benefit from anti-
coagulant therapy [10].
The rheumatologist perspective: histopathological
findings of arterial thrombosis in the splenic hilum
(Fig. 1C–E) appear to be related to a neutrophilic vascu-
litis process. These findings share similarities with those
described in the acute stage of polyarteritis nodosa
(PAN), a medium-sized vessel vasculitis [11] that recog-
nizes an immune-pathogenetic mechanism sometimes
associated with viral infections. Similarly to PAN, this
patient presented gastrointestinal and splenic involve-
ment with ischaemic complications. However, his clinical
condition improved without immunosuppressive treat-
ment while he was using anticoagulant therapy
similar to that indicated in thrombotic complications of
PAN [12].
The pneumologist perspective: in patients with
COVID-19, lung involvement is sustained by direct viral
infection alongside cytokine-driven endothelial damage
that enhances local inflammation and promotes pulmon-
ary vascular micro-thrombosis [13]. Given these prem-
ises, pulmonary vasculitis may enhance lung damage,
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increasing interstitial involvement with significant deteri-
oration of lung elastance without affecting compliance
[13]. The low amount of non-aerated tissue justifies the
low recruitability, mimicking the mechanical model of
interstitial lung disorders [14–16] and explaining the
presence of shortness of breath on admission despite
FIG. 1 Arterial and venous thrombotic complications and neutrophilic vasculitis in splenic artery
(A) Thrombosis of the coeliac tripod immediately after its origin, extended to 15 mm. The superior mesenteric artery
presents thrombosis as well as some of its branches. Almost complete infarction of an ileal segment and spleen.
(B–E) All anatomic specimens were fixed in 4% neutral buffered formaldehyde and, after paraffin embedding, 3 micra
thick sections were cut and routinely stained with haematoxylin and eosin (HE). (B) Venous vessel of the splenic hilum
with fibrin thrombus in the lumen. HE, 100 (original magnification). (C) Wall of the splenic artery with fibrin thrombus
in the lumen and granulocytic infiltration. HE, 100 (original magnification). (D) High magnification of the splenic artery
showing transmural infiltration of neutrophils, from adventitia (top) to intima (bottom left). HE, 200 (original magnifi-
cation). (E) Diffuse infiltration of neutrophilic granulocytes in the arterial wall. HE, 1000 (original magnification).
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lack of respiratory failure or significant parenchymal in-
volvement. Moreover, pulmonary vasculitis might extend
the loss of hypoxic vasoconstriction, preventing the
compensation mechanism of vascular redistribution in
inhomogeneous lungs, with further dysregulation of al-
veolar micro-perfusion and increased risk of micro-
thrombosis15.
The nephrologist perspective: The patient presented
severe acute kidney injury (AKI) requiring renal replace-
ment therapy in the context of diabetes-related CKD.
The differential diagnosis of AKI in a setting of systemic
vasculitis included ‘kidney vasculitis’ and acute tubular
necrosis.
Widespread inflammation of the medium-sized vessels
is a potential, albeit rare, cause of rapidly progressive
renal failure. Fibrinoid necrosis of the arterial wall may
involve smaller vessels such as interlobar and arcuate
arteries resulting in AKI due to glomerular hypoperfusion
and tubular necrosis [17]. Conversely, the abrupt decline
of renal function after major abdominal surgery sug-
gested tubular necrosis as a potential cause of kidney
failure. Pre-existent chronic kidney injury, diabetes, pro-
longed surgical time and concomitant use of contrast
media were recognized risk factors responsible for
developing AKI. Although the partial recovery of kidney
function without immunosuppressive therapy may sug-
gest pre-renal status and nephrotoxicity as aetiology of
kidney injury, we cannot exclude the possibility that
resolution of the viral infection attenuated the immune
response and led to a partial improvement of renal func-
tion. In the absence of renal biopsy, the aetiology of AKI
remains elusive.
The multidisciplinary perspective presented above elu-
cidates a very novel and significant disease pathophysi-
ology in the context of COVID-19.
Norsa et al. described the case of a 62-year-old man
presenting a picture of small bowel ischaemia, thrombo-
embolic filling defects in inferior vena cava and superior
mesenteric vein. The patient was tested for SARS-CoV-
2 and was found negative in nasopharyngeal swab and
bronco-alveolar lavage. The histological examination on
the resected small bowel showed complete ischaemic
necrosis of the mucosal layer and acute perivisceral in-
flammation; the mesenteric vessel was characterized by
complete recent thrombosis and mixed inflammatory in-
filtration of arterial and venous vessels mainly involving
the endothelium [9]. On the contrary, we observed a
vasculitic involvement constituted by neutrophilic infiltra-
tion of adventitia and media.
Furthermore, the authors detected a SARS-CoV-2
trough in situ hybridization in a resected ischaemic small
bowel, suggesting a direct viral role in the ischaemic
process. In our case, the lack of the detection of SARS-
CoV-2 could be due to a low sensitivity of RT-PCR com-
pared with RNA in situ hybridization or to a real absence
of the virus in the examined specimens, allowing us to
speculate that the viral infection could represent a trig-
ger for a cascade of systemic inflammatory-mediated
events [18].
The main limitation in this analysis is related to a
scarce availability of diagnostic procedures.
Furthermore, data available do not permit an estimation
of the size effect of COVID-19 neutrophilic vasculitis on
the overall burden of thrombotic complication, as the CT
scan also shows severe atheromatosis, which can wor-
sen the complex clinical picture of our patient.
Based on the hypothesis of a relationship between
SARS-CoV-2 infection and our PAN-like disorder, treat-
ment with a short course of glucocorticoids and/or
plasma exchange could represent a therapeutic option
as had been observed by Guillevin et al. in HBsAg-
related PAN [19, 20]. However, the patient was not
treated with glucocorticoids and/or traditional immuno-
suppressive treatment because there was a spontan-
eous improvement with supportive treatment.
In conclusion, it is conceivable to attribute a leading
role to anticoagulant treatments in the management of
COVID-19. Nevertheless, while primary LMWH may be
effective in the prevention of endothelial activation-
induced thrombosis, this might not be the case when
thrombotic phenomena are secondary to vasculitis,
which could benefit from immunosuppressive therapy.
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